Lilly commits $3bn to Wisconsin facility to boost injectable medicine production
Eli Lilly and Company (Lilly) has unveiled plans for a $3 billion expansion of its newly acquired manufacturing facility in Kenosha County, Wisconsin, signalling a ... Read More
Could this startup have the cure for obesity? Meet Pep2Tango Therapeutics!
Versant Ventures has introduced Pep2Tango Therapeutics Inc., a biotechnology startup dedicated to pioneering next-generation therapies for weight loss. The company has secured significant, albeit undisclosed, ... Read More
Eli Lilly to expand manufacturing with $1bn investment in Ireland to boost Alzheimer’s drug production
Eli Lilly and Company (NYSE: LLY) has announced a substantial $1 billion investment to expand its Limerick, Ireland, manufacturing site, which will increase the production ... Read More
Eli Lilly’s tirzepatide shows promising results for obstructive sleep apnea in latest clinical trials
Eli Lilly and Company (NYSE: LLY) has announced promising results from the SURMOUNT-OSA phase 3 clinical trials of tirzepatide, a novel treatment aimed at moderate-to-severe ... Read More
NeuroBo Pharmaceuticals’ DA-1726 shows promising results in pre-clinical obesity treatment studies
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology firm, announced promising pre-clinical data for DA-1726, a novel oxyntomodulin (OXM) analog functioning as a dual agonist ... Read More
Sun Pharmaceutical’s GL0034 study reveals promising obesity treatment outcomes
Sun Pharmaceutical Industries Limited unveiled data from its Phase 1 study of GL0034 (Utreglutide), targeting obesity in adults. The findings, presented at the 84th American ... Read More
Zealand Pharma announces promising results from dapiglutide trial for obesity treatment
Zealand Pharma A/S (Nasdaq: ZEAL), a pioneer in peptide-based drug development, has shared topline results from its DREAM trial, evaluating the efficacy of low doses ... Read More
Roche’s CT-388 shows promising results in Phase I trial for obesity and Type 2 diabetes treatment
Roche has announced positive outcomes from the Phase I clinical trial of CT-388, a novel dual GLP-1/GIP receptor agonist, which is being developed as a ... Read More
FDA approves Novo Nordisk’s Wegovy for cardiovascular risk reduction in adults with obesity
The U.S. Food and Drug Administration (FDA) has recently granted an additional indication for Novo Nordisk's Wegovy, a milestone in medical advancements aimed at combating ... Read More